Fibrosarcoma

Identification of PLAG1 rearrangement is crucial for confirming the diagnosis. With the growing number of molecularly defined soft-tissue tumours of diagnostic and prognostic significance, incorporating molecular analysis is essential in the evaluation of soft-tissue lesions.

Larotrectinib shows meaningful efficacy and favorable tolerance across NTRK fusion-positive malignancies beyond IFS. These real-world data support early molecular testing, highlight histology-dependent outcomes, and inform clinical management strategies.

DFSP appears biologically optimized for local stromal infiltration rather than systemic dissemination. Rare metastatic progression likely reflects the acquisition of additional molecular and microenvironmental features, particularly in fibrosarcomatous transformation. Further investigation into stromal interactions and vascular access mechanisms is warranted.

The framework reframes NRF2 pharmacology around one principle: the most actionable target is often a partner rather than NRF2 itself, with disease context dictating the direction of modulation. We close with five testable hypotheses and a partner-code decision matrix linking disease, biomarker, and candidate target.

FTH upregulation mitigates iron toxicity through ferroxidase activity, while SQSTM1 modulates lipid peroxidation in ferroptosis. These findings provide a preliminary transcriptomic landscape for hypothesis generation regarding ncRNA-mediated regulatory mechanisms in iron overload-induced ferroptosis and offer a computational foundation for future functional and therapeutic investigations.

PTGS2hi Breghi patients were associated with a poor survival rate, while the COX-2 inhibitor NS-398 prevented tBreg generation and reduced tumor burden. This could lead to the development of novel strategies for reducing tBreg production in cancer.

SerpinB9 overexpression is associated with fibrosarcomatous features in DFSP and may represent a candidate prognosis biomarker. The SF3B/SERPINB9 axis is a potential therapeutic vulnerability, particularly in FS-DFSP. NK cell- and macrophage-related signatures were evident in DFSP tumor microenvironment, warranting further functional studies.

Furthermore, a novel oral nanoparticle delivery system, targeting the liver tissue, enhances the therapeutic efficacy of sorafenib, restoring liver enzyme levels by up to 76%. Collectively, these findings identify middle-dose sorafenib, particularly when delivered via the novel oral nanoplatform, as an effective strategy to mitigate hepatic IRI.

P2/3, N=140, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026

A deep-seated soft-tissue mass displaying heterogeneous T2 signal with hypointense collagenous areas and progressive enhancement should raise suspicion for sclerosing epithelioid fibrosarcoma, especially in atypical locations such as the iliac fossa. Definitive diagnosis requires histopathology and immunohistochemistry (MUC4), while long-term follow-up is essential to monitor late recurrence or metastasis.

Cucurbitacin B-induced TNF-R1 shedding was attenuated by TNF-α protease inhibitor 2 and the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor U0126, but not by the p38 MAPK inhibitor SB203580 or the c-Jun N-terminal kinase (JNK) inhibitor SP600125. Consistent with these results, cucurbitacin B promoted the rapid phosphorylation of rapidly accelerated fibrosarcoma 1 (RAF1) and ERK, but exerted minimal effects on the phosphorylation of p38 MAPK and JNK. Collectively, these results demonstrate that cucurbitacin B selectively activated the RAF1-MEK-ERK pathway, which was essential for TNF-R1 ectodomain shedding.